Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soticlestat QTc Interval Study in Healthy Adults
NCT05309902Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Oct 2022
- Primary completion
- Dec 2022
01
Overview
Phase 1, randomised, double-blind trial of soticlestat in epilepsy (4 arms), sponsored by Takeda. Primary endpoint: Placebo-corrected Change From Baseline in Corrected QT Interval. Planned start Oct 2022; status: withdrawn.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05309902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309902.